IL28B Assay

Chronic HCV infection affects around 3% IL28B pcrof the world population and is the leading cause of cirrhosis, liver cancer and liver transplantation. Pegylated interferon/ribavirin (pegIFN/RBV) therapy is the treatment of choice for HCV infection. SRV is dependent on virus genotype as well as on patients‘ factors including genetic polymorphisms.

IL28B RealFast™ Assay is the accurate way to test the therapeutic response of antiviral therapy in Hepatitis C Virus (HCV) infected patients. It helps to predict the success of antiviral therapy and sustained virologic response (SVR) in HCV infected patients. The TT>∆G variant in the IFNL4 gene is the strongest known host factor for predicting HCV clearance. Genotyping of TT>∆G helps to predict the outcome of pegIFN/RBV therapy independent of a patient‘s ethnicity. IL28B pcr IL28B pcr

RealFast™ Assays technology

The ViennaLab RealFast™ Assays are based on real-time PCR and hydrolysis probes, also commonly called TaqMan® probes. The sequence-specific oligonucleotide probes carry a fluorescent reporter dye at the 5´-end and a quencher dye at the 3´-end. While the probe is intact, the quencher is close enough to the reporter to suppress the fluorescent signal of the 5´-fluorophore. During the combined annealing/extension phase of PCR, the probe is cleaved by the 5´ to 3´ exonuclease activity of Taq DNA polymerase, thereby separating the fluorophore from the quencher dye. This process results in detectable fluorescence, which is proportional to the amount of accumulated PCR product.

IL28B RealFast™ Assay7-200100 reactionsdetects HCV clearance
IL28B RealFast™ Assay7-20332 reactionsdetects HCV clearance